Abstracts
PO106
Temporal Trends in Multiple Myeloma-Associated Chronic Kidney Disease Mortality in the United States, 1999-2025: A CDC WONDER Analysis
Introduction/Background/Significance: Chronic kidney disease (CKD) is a major complication of multiple myeloma (MM) and contributes substantially to morbidity and mortality. Contemporary national trends in MM-associated CKD mortality remain insufficiently characterized. We evaluated long-term mortality trends and demographic disparities in MM-associated CKD deaths in the United States.
Materials and Methods/Case Presentation/Objective: We conducted a population-based analysis using the CDC WONDER Multiple Cause of Death database (1999-2025). Deaths with multiple myeloma (ICD-10: C90) and chronic kidney disease (ICD-10: N17-N19) listed on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals (95% CIs) overall and stratified by sex, age, race/ethnicity, census region, and urban-rural status.
Results/Description/Main Outcome Measure(s): A total of 65,257 MM-associated CKD deaths were identified. The overall AAMR declined from 1.31 per 100,000 in 1999 to 0.84 in 2024. Overall mortality decreased significantly throughout the study period (AAPC −2.19%, 95% CI −2.77 to −1.61; P< 0.000001). Declining trends were observed in both females (AAPC −2.61%) and males (AAPC −1.98%). By age, mortality decreased significantly among individuals aged 45-54 (AAPC −2.50%), 55-64 (−2.73%), 65-74 (−2.53%), and 75-84 years (−1.95%), whereas no significant overall change was observed among adults aged ≥85 years (AAPC 0.02%, P=0.883), despite a significant increase after 2018 (APC 3.00%). Mortality declined across racial and ethnic groups, including Hispanics (AAPC −2.38%), Asian/Pacific Islanders (−2.49%), Black individuals (−2.09%), and White individuals (−2.14%). Regionally, the Northeast demonstrated the greatest decline (AAPC −2.84%), followed by the West (−2.06%), South (−1.97%), and Midwest (−1.51%). Across urban-rural categories, mortality declined significantly in all groups, with the largest decrease observed in Large Central Metropolitan counties (AAPC −2.29%), followed by Large Fringe Metropolitan (−2.11%), Noncore Nonmetropolitan (−2.04%), Medium Metropolitan (−1.95%), Small Metropolitan (−1.76%), and Micropolitan counties (−1.71%).
Conclusion(s).:
Trademarked Items:
References: Temporal Trends, Multiple Myeloma, Chronic Kidney Disease, CDC WONDER Analysis, Joinpoint regression
Materials and Methods/Case Presentation/Objective: We conducted a population-based analysis using the CDC WONDER Multiple Cause of Death database (1999-2025). Deaths with multiple myeloma (ICD-10: C90) and chronic kidney disease (ICD-10: N17-N19) listed on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals (95% CIs) overall and stratified by sex, age, race/ethnicity, census region, and urban-rural status.
Results/Description/Main Outcome Measure(s): A total of 65,257 MM-associated CKD deaths were identified. The overall AAMR declined from 1.31 per 100,000 in 1999 to 0.84 in 2024. Overall mortality decreased significantly throughout the study period (AAPC −2.19%, 95% CI −2.77 to −1.61; P< 0.000001). Declining trends were observed in both females (AAPC −2.61%) and males (AAPC −1.98%). By age, mortality decreased significantly among individuals aged 45-54 (AAPC −2.50%), 55-64 (−2.73%), 65-74 (−2.53%), and 75-84 years (−1.95%), whereas no significant overall change was observed among adults aged ≥85 years (AAPC 0.02%, P=0.883), despite a significant increase after 2018 (APC 3.00%). Mortality declined across racial and ethnic groups, including Hispanics (AAPC −2.38%), Asian/Pacific Islanders (−2.49%), Black individuals (−2.09%), and White individuals (−2.14%). Regionally, the Northeast demonstrated the greatest decline (AAPC −2.84%), followed by the West (−2.06%), South (−1.97%), and Midwest (−1.51%). Across urban-rural categories, mortality declined significantly in all groups, with the largest decrease observed in Large Central Metropolitan counties (AAPC −2.29%), followed by Large Fringe Metropolitan (−2.11%), Noncore Nonmetropolitan (−2.04%), Medium Metropolitan (−1.95%), Small Metropolitan (−1.76%), and Micropolitan counties (−1.71%).
Conclusion(s).:
MM-associated CKD mortality in the United States declined significantly from 1999 to 2025, with consistent reductions across sexes, most age groups, racial/ethnic populations, geographic regions, and urban-rural settings. However, the recent increase in mortality among adults aged ≥85 years underscores a persistent high-risk population that may benefit from earlier recognition of kidney involvement, optimized supportive renal care, and continued advances in myeloma-directed therapies
Trademarked Items:
References: Temporal Trends, Multiple Myeloma, Chronic Kidney Disease, CDC WONDER Analysis, Joinpoint regression
